An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis

Xiumei Huang, Ying Dong, Erik A. Bey, Jessica A. Kilgore, Joseph S. Bair, Long Shan Li, Malina Patel, Elizabeth I. Parkinson, Yiguang Wang, Noelle S. Williams, Jinming Gao, Paul J. Hergenrother, David A. Boothman

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Agents, such as β-lapachone, that target the redox enzyme, NAD(P)H:quinone oxidoreductase 1 (NQO1), to induce programmed necrosis in solid tumors have shown great promise, but more potent tumor-selective compounds are needed. Here, we report that deoxynyboquinone kills a wide spectrum of cancer cells in an NQO1-dependent manner with greater potency than β-lapachone. Deoxynyboquinone lethality relies on NQO1-dependent futile redox cycling that consumes oxygen and generates extensive reactive oxygen species (ROS). Elevated ROS levels cause extensive DNA lesions, PARP1 hyperactivation, and severe NAD+/ATP depletion that stimulate Ca2+-dependent programmed necrosis, unique to this new class of NQO1 "bioactivated" drugs. Shortterm exposure of NQO1+ cells to deoxynyboquinone was sufficient to trigger cell death, although genetically matched NQO1- cells were unaffected. Moreover, siRNA-mediated NQO1 or PARP1 knockdown spared NQO1+ cells from short-term lethality. Pretreatment of cells with BAPTA-AM (a cytosolic Ca2+ chelator) or catalase (enzymatic H2O2 scavenger) was sufficient to rescue deoxynyboquinone-induced lethality, as noted with β-lapachone. Investigations in vivo showed equivalent antitumor efficacy of deoxynyboquinone to β-lapachone, but at a 6-fold greater potency. PARP1 hyperactivation and dramatic ATP loss were noted in the tumor, but not in the associated normal lung tissue. Our findings offer preclinical proof-of-concept for deoxynyboquinone as a potent chemotherapeutic agent for treatment of a wide spectrum of therapeutically challenging solid tumors, such as pancreatic and lung cancers.

Original languageEnglish (US)
Pages (from-to)3038-3047
Number of pages10
JournalCancer Research
Volume72
Issue number12
DOIs
StatePublished - Jun 15 2012

Fingerprint

Necrosis
Neoplasms
NAD
Oxidation-Reduction
Reactive Oxygen Species
Adenosine Triphosphate
Substrate Cycling
Chelating Agents
Pancreatic Neoplasms
Catalase
Small Interfering RNA
deoxynyboquinone
Lung Neoplasms
Oxidoreductases
Cell Death
Oxygen
Lung
DNA
Enzymes
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis. / Huang, Xiumei; Dong, Ying; Bey, Erik A.; Kilgore, Jessica A.; Bair, Joseph S.; Li, Long Shan; Patel, Malina; Parkinson, Elizabeth I.; Wang, Yiguang; Williams, Noelle S.; Gao, Jinming; Hergenrother, Paul J.; Boothman, David A.

In: Cancer Research, Vol. 72, No. 12, 15.06.2012, p. 3038-3047.

Research output: Contribution to journalArticle

Huang, X, Dong, Y, Bey, EA, Kilgore, JA, Bair, JS, Li, LS, Patel, M, Parkinson, EI, Wang, Y, Williams, NS, Gao, J, Hergenrother, PJ & Boothman, DA 2012, 'An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis', Cancer Research, vol. 72, no. 12, pp. 3038-3047. https://doi.org/10.1158/0008-5472.CAN-11-3135
Huang, Xiumei ; Dong, Ying ; Bey, Erik A. ; Kilgore, Jessica A. ; Bair, Joseph S. ; Li, Long Shan ; Patel, Malina ; Parkinson, Elizabeth I. ; Wang, Yiguang ; Williams, Noelle S. ; Gao, Jinming ; Hergenrother, Paul J. ; Boothman, David A. / An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis. In: Cancer Research. 2012 ; Vol. 72, No. 12. pp. 3038-3047.
@article{51ea1821719c4ad1a9a86f1f22d9602d,
title = "An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis",
abstract = "Agents, such as β-lapachone, that target the redox enzyme, NAD(P)H:quinone oxidoreductase 1 (NQO1), to induce programmed necrosis in solid tumors have shown great promise, but more potent tumor-selective compounds are needed. Here, we report that deoxynyboquinone kills a wide spectrum of cancer cells in an NQO1-dependent manner with greater potency than β-lapachone. Deoxynyboquinone lethality relies on NQO1-dependent futile redox cycling that consumes oxygen and generates extensive reactive oxygen species (ROS). Elevated ROS levels cause extensive DNA lesions, PARP1 hyperactivation, and severe NAD+/ATP depletion that stimulate Ca2+-dependent programmed necrosis, unique to this new class of NQO1 {"}bioactivated{"} drugs. Shortterm exposure of NQO1+ cells to deoxynyboquinone was sufficient to trigger cell death, although genetically matched NQO1- cells were unaffected. Moreover, siRNA-mediated NQO1 or PARP1 knockdown spared NQO1+ cells from short-term lethality. Pretreatment of cells with BAPTA-AM (a cytosolic Ca2+ chelator) or catalase (enzymatic H2O2 scavenger) was sufficient to rescue deoxynyboquinone-induced lethality, as noted with β-lapachone. Investigations in vivo showed equivalent antitumor efficacy of deoxynyboquinone to β-lapachone, but at a 6-fold greater potency. PARP1 hyperactivation and dramatic ATP loss were noted in the tumor, but not in the associated normal lung tissue. Our findings offer preclinical proof-of-concept for deoxynyboquinone as a potent chemotherapeutic agent for treatment of a wide spectrum of therapeutically challenging solid tumors, such as pancreatic and lung cancers.",
author = "Xiumei Huang and Ying Dong and Bey, {Erik A.} and Kilgore, {Jessica A.} and Bair, {Joseph S.} and Li, {Long Shan} and Malina Patel and Parkinson, {Elizabeth I.} and Yiguang Wang and Williams, {Noelle S.} and Jinming Gao and Hergenrother, {Paul J.} and Boothman, {David A.}",
year = "2012",
month = "6",
day = "15",
doi = "10.1158/0008-5472.CAN-11-3135",
language = "English (US)",
volume = "72",
pages = "3038--3047",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis

AU - Huang, Xiumei

AU - Dong, Ying

AU - Bey, Erik A.

AU - Kilgore, Jessica A.

AU - Bair, Joseph S.

AU - Li, Long Shan

AU - Patel, Malina

AU - Parkinson, Elizabeth I.

AU - Wang, Yiguang

AU - Williams, Noelle S.

AU - Gao, Jinming

AU - Hergenrother, Paul J.

AU - Boothman, David A.

PY - 2012/6/15

Y1 - 2012/6/15

N2 - Agents, such as β-lapachone, that target the redox enzyme, NAD(P)H:quinone oxidoreductase 1 (NQO1), to induce programmed necrosis in solid tumors have shown great promise, but more potent tumor-selective compounds are needed. Here, we report that deoxynyboquinone kills a wide spectrum of cancer cells in an NQO1-dependent manner with greater potency than β-lapachone. Deoxynyboquinone lethality relies on NQO1-dependent futile redox cycling that consumes oxygen and generates extensive reactive oxygen species (ROS). Elevated ROS levels cause extensive DNA lesions, PARP1 hyperactivation, and severe NAD+/ATP depletion that stimulate Ca2+-dependent programmed necrosis, unique to this new class of NQO1 "bioactivated" drugs. Shortterm exposure of NQO1+ cells to deoxynyboquinone was sufficient to trigger cell death, although genetically matched NQO1- cells were unaffected. Moreover, siRNA-mediated NQO1 or PARP1 knockdown spared NQO1+ cells from short-term lethality. Pretreatment of cells with BAPTA-AM (a cytosolic Ca2+ chelator) or catalase (enzymatic H2O2 scavenger) was sufficient to rescue deoxynyboquinone-induced lethality, as noted with β-lapachone. Investigations in vivo showed equivalent antitumor efficacy of deoxynyboquinone to β-lapachone, but at a 6-fold greater potency. PARP1 hyperactivation and dramatic ATP loss were noted in the tumor, but not in the associated normal lung tissue. Our findings offer preclinical proof-of-concept for deoxynyboquinone as a potent chemotherapeutic agent for treatment of a wide spectrum of therapeutically challenging solid tumors, such as pancreatic and lung cancers.

AB - Agents, such as β-lapachone, that target the redox enzyme, NAD(P)H:quinone oxidoreductase 1 (NQO1), to induce programmed necrosis in solid tumors have shown great promise, but more potent tumor-selective compounds are needed. Here, we report that deoxynyboquinone kills a wide spectrum of cancer cells in an NQO1-dependent manner with greater potency than β-lapachone. Deoxynyboquinone lethality relies on NQO1-dependent futile redox cycling that consumes oxygen and generates extensive reactive oxygen species (ROS). Elevated ROS levels cause extensive DNA lesions, PARP1 hyperactivation, and severe NAD+/ATP depletion that stimulate Ca2+-dependent programmed necrosis, unique to this new class of NQO1 "bioactivated" drugs. Shortterm exposure of NQO1+ cells to deoxynyboquinone was sufficient to trigger cell death, although genetically matched NQO1- cells were unaffected. Moreover, siRNA-mediated NQO1 or PARP1 knockdown spared NQO1+ cells from short-term lethality. Pretreatment of cells with BAPTA-AM (a cytosolic Ca2+ chelator) or catalase (enzymatic H2O2 scavenger) was sufficient to rescue deoxynyboquinone-induced lethality, as noted with β-lapachone. Investigations in vivo showed equivalent antitumor efficacy of deoxynyboquinone to β-lapachone, but at a 6-fold greater potency. PARP1 hyperactivation and dramatic ATP loss were noted in the tumor, but not in the associated normal lung tissue. Our findings offer preclinical proof-of-concept for deoxynyboquinone as a potent chemotherapeutic agent for treatment of a wide spectrum of therapeutically challenging solid tumors, such as pancreatic and lung cancers.

UR - http://www.scopus.com/inward/record.url?scp=84862566809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862566809&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-11-3135

DO - 10.1158/0008-5472.CAN-11-3135

M3 - Article

C2 - 22532167

AN - SCOPUS:84862566809

VL - 72

SP - 3038

EP - 3047

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 12

ER -